TASK‑1 induces gefitinib resistance by promoting cancer initiating cell formation and epithelial‑mesenchymal transition in lung cancer

  • Authors:
    • Xing‑Guang Wang
    • Na‑Xin Yuan
    • Xin‑Peng Li
    • Fang‑Fang Chen
  • View Affiliations

  • Published online on: November 1, 2017     https://doi.org/10.3892/etm.2017.5426
  • Pages:365-370
Metrics: HTML 0 views | PDF 0 views
0

Abstract

Cancer initiating cell (CIC) formation and epithelial‑mesenchymal transition (EMT) are pivotal events in lung cancer cell invasion and metastasis. They have been shown to occur in gefitinib resistance. Studying the molecular mechanisms of CICs, EMT and acquired gefitinib resistance will enhance the understanding of the pathogenesis and progression of the disease and offer novel targets for effective therapies. TWIK‑related acid‑sensitive K(+) (TASK‑1) is expressed in a subset of non‑small‑cell lung cancer (NSCLC) cell lines, where it promotes cell proliferation while inhibiting apoptosis. In the present study, TASK‑1 was demonstrated to induce gefitinib resistance in the A549 NSCLC cell line. Overexpression of TASK‑1 promoted the acquisition of CIC‑like traits by A549 cells. CD133, octamer‑binding transcription factor 4 (OCT‑4) and Nanog have been suggested to be markers of CICs in lung cancer. It was demonstrated that overexpression of TASK‑1 promoted CD133, OCT‑4 and Nanog protein expression in A549 cells. Increased formation of stem cell‑like populations results in EMT of cancer cells. The present study found that overexpression of TASK‑1 promoted EMT of A549 cells. Thus, downregulation of TASK‑1 may represent a novel strategy for EMT reversal, decreasing CIC‑like traits and increasing gefitinib sensitivity of NSCLCs.

Related Articles

Journal Cover

January 2018
Volume 15 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

2016 Impact Factor: 1.261
Ranked #50/128 Medicine Research and Experimental
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wang, X., Yuan, N., Li, X., & Chen, F. (2018). TASK‑1 induces gefitinib resistance by promoting cancer initiating cell formation and epithelial‑mesenchymal transition in lung cancer. Experimental and Therapeutic Medicine, 15, 365-370. https://doi.org/10.3892/etm.2017.5426
MLA
Wang, X., Yuan, N., Li, X., Chen, F."TASK‑1 induces gefitinib resistance by promoting cancer initiating cell formation and epithelial‑mesenchymal transition in lung cancer". Experimental and Therapeutic Medicine 15.1 (2018): 365-370.
Chicago
Wang, X., Yuan, N., Li, X., Chen, F."TASK‑1 induces gefitinib resistance by promoting cancer initiating cell formation and epithelial‑mesenchymal transition in lung cancer". Experimental and Therapeutic Medicine 15, no. 1 (2018): 365-370. https://doi.org/10.3892/etm.2017.5426